Insider Selling: RxSight, Inc. (NASDAQ:RXST) Director Sells $108,631.53 in Stock

RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar sold 3,519 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total transaction of $108,631.53. Following the completion of the transaction, the director now owns 7,383 shares in the company, valued at $227,913.21. The trade was a 32.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shweta Maniar also recently made the following trade(s):

• On Tuesday, November 26th, Shweta Maniar sold 3,782 shares of RxSight stock. The stock was sold at an average price of $45.88, for a total value of $173,518.16.

RxSight Stock Performance

Shares of RXST opened at $31.58 on Thursday. The firm’s 50-day simple moving average is $36.84 and its two-hundred day simple moving average is $45.44. RxSight, Inc. has a fifty-two week low of $26.29 and a fifty-two week high of $66.54. The stock has a market cap of $1.27 billion, a PE ratio of -38.05 and a beta of 1.20.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.18). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $35.31 million for the quarter, compared to the consensus estimate of $35.15 million. During the same period last year, the business earned ($0.35) EPS. Equities research analysts predict that RxSight, Inc. will post -0.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RXST. Jefferies Financial Group initiated coverage on RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective for the company. Wells Fargo & Company dropped their price target on RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. UBS Group assumed coverage on shares of RxSight in a research report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a research report on Monday, January 13th. Finally, Stifel Nicolaus reduced their price target on shares of RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.13.

Hedge Funds Weigh In On RxSight

A number of hedge funds have recently bought and sold shares of the company. Brown Capital Management LLC purchased a new position in RxSight in the third quarter worth about $26,813,000. Point72 Asset Management L.P. raised its holdings in RxSight by 610.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after acquiring an additional 384,041 shares during the last quarter. Thrivent Financial for Lutherans purchased a new position in RxSight in the 3rd quarter worth approximately $11,350,000. RA Capital Management L.P. lifted its position in RxSight by 6.0% in the 3rd quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock valued at $193,609,000 after acquiring an additional 222,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in RxSight by 17.7% during the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock valued at $40,398,000 after purchasing an additional 122,775 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.